Medical treatment of glaucoma
Every glaucoma drug lowers intraocular pressure, and each does it by acting on one step of aqueous production or drainage. This lesson takes the classes in turn: how each works, how well, what it does to the eye and the rest of the body, and when it must not be used. Contraindications and doses follow the BNF.
Two ways to lower pressure
Intraocular pressure depends on how fast aqueous is made and how easily it leaves. A drug can therefore lower pressure in only two ways: by reducing secretion from the ciliary processes, or by increasing outflow through the trabecular or the uveoscleral route. Knowing which a drug does lets you predict how drugs combine. Two that act by different mechanisms add together. Two that both suppress production add little.
3D atlasDrug targets: the ciliary processes (production), the trabecular meshwork and Schlemm's canal (conventional outflow) and the ciliary body (uveoscleral outflow).| Class | Examples | Main action | Typical frequency |
|---|---|---|---|
| Prostaglandin analogues | Latanoprost, travoprost, tafluprost, bimatoprost | Increase uveoscleral outflow | Once daily, in the evening |
| Beta-blockers | Timolol, betaxolol, levobunolol | Reduce aqueous production | Twice daily, or once daily for long-acting forms |
| Carbonic anhydrase inhibitors | Dorzolamide, brinzolamide (topical), acetazolamide (systemic) | Reduce aqueous production | Two or three times daily |
| Sympathomimetics (alpha-2 agonists) | Brimonidine, apraclonidine | Reduce aqueous production; brimonidine also increases uveoscleral outflow | Twice daily (brimonidine) |
| Miotics | Pilocarpine | Increase trabecular outflow | Up to four times daily |
| Rho kinase inhibitors | Netarsudil (with latanoprost) | Increase trabecular outflow | Once daily, in the evening |
Prostaglandin analogues give the largest fall, around 30 per cent. Beta-blockers lower pressure by roughly 20 to 30 per cent, and the other classes by somewhat less. NICE recommends a generic prostaglandin analogue as the first-line drug, with a beta-blocker next if prostaglandins are not tolerated.
Prostaglandin analogues
Latanoprost is an inactive ester that crosses the cornea and is hydrolysed there to the active acid. It increases uveoscleral outflow, probably by switching on matrix metalloproteinases that remodel the extracellular matrix between the ciliary muscle bundles, so aqueous seeps through more easily. Bimatoprost is a closely related synthetic prostamide with the same clinical use.
The class owes its first-line position to three things: the largest pressure reduction, once-daily dosing, and very few systemic effects. Its adverse effects are mostly local and cosmetic, but some are permanent, so patients must be warned before starting.
- Conjunctival hyperaemia (a red eye), commonest in the first weeks.
- Darkening of the iris, from increased melanin within the iris melanocytes, not from an increase in their number. It is most noticeable in mixed-colour irides, may be permanent, and matters most when only one eye is treated.
- Longer, thicker, darker eyelashes, and pigmentation or hair growth on skin that the drops touch.
- Loss of fat around the eye, giving a deep upper lid sulcus.
- Cystoid macular oedema, mainly in eyes with risk factors such as aphakia or a torn posterior capsule after cataract surgery.
- Reactivation of herpes simplex keratitis, and anterior uveitis.
The BNF lists active herpes simplex keratitis, and a history of recurrent herpetic keratitis associated with prostaglandin analogues, as contraindications to latanoprost. Cautions include aphakia, pseudophakia with a torn posterior capsule, risk factors for cystoid macular oedema, iritis or uveitis, and asthma. The manufacturer advises avoiding it in pregnancy and breast-feeding.
Beta-blockers
Sympathetic stimulation of beta receptors on the ciliary epithelium drives aqueous secretion. Timolol, a non-selective beta-blocker, blocks this and reduces production. Betaxolol is beta-1 selective. Because aqueous production already falls by about half during sleep, beta-blockers add little overnight.
Locally they are well tolerated, causing little more than stinging and dry eye. The danger is systemic. A drop that drains down the nasolacrimal duct is absorbed through the nasal mucosa straight into the circulation, avoiding the first-pass metabolism in the liver that an oral dose undergoes. A topical beta-blocker can therefore cause bradycardia, heart block, hypotension and bronchospasm.
The BNF applies the contraindications of systemic beta-blockers to the eye drops: asthma, marked bradycardia, second-degree or third-degree heart block, and uncontrolled heart failure. A history of obstructive airways disease calls for caution, even with a cardioselective drug. They can mask the symptoms of hypoglycaemia in diabetes, and combining them with verapamil or diltiazem risks heart block.
Carbonic anhydrase inhibitors
The ciliary epithelium secretes aqueous by pumping ions, including bicarbonate, into the posterior chamber, with water following. Carbonic anhydrase generates that bicarbonate. Blocking the enzyme slows secretion.
Dorzolamide and brinzolamide are topical. Dorzolamide is used three times daily alone, or twice daily with a beta-blocker, and is available in a fixed combination with timolol. The drops sting and leave a bitter taste as they drain into the throat. They are sulfonamide derivatives and some is absorbed. The BNF contraindicates both in hyperchloraemic acidosis. For sulfonamide hypersensitivity it lists brinzolamide as contraindicated and dorzolamide as a caution. Dorzolamide is also used with caution when the corneal endothelial cell count is low.
Acetazolamide is given by mouth or intravenously, at 0.25 to 1 g daily in divided doses. It lowers pressure quickly and substantially and is mostly used for short periods: in acute angle closure, for very high pressures in secondary glaucoma, and around surgery. Its adverse effects limit long-term use.
- Paraesthesia (tingling of the extremities), fatigue, nausea and altered taste.
- Metabolic acidosis and electrolyte disturbance including hypokalaemia, because bicarbonate is lost in the urine.
- Renal stones.
- Rarely, blood disorders and severe skin reactions, as with other sulfonamides.
The BNF contraindicates acetazolamide in sulfonamide hypersensitivity, hypokalaemia, hyponatraemia, hyperchloraemic acidosis and adrenocortical insufficiency, and advises avoiding it in renal and hepatic impairment. Blood count and electrolytes are monitored with prolonged use.
Sympathomimetics and miotics
Brimonidine is a selective alpha-2 adrenoceptor agonist. It reduces aqueous production and is also thought to increase uveoscleral outflow. It is used twice daily when beta-blockers are inappropriate or as an added drug. Its main local problem is allergy: an itchy, red eye with follicles on the conjunctiva. Systemically it causes a dry mouth, drowsiness and fatigue, and it is avoided in infants and young children because of central nervous system depression.
Apraclonidine is a related drug whose effect wears off with continued use. Its main role is a single drop before and after anterior segment laser, to prevent a spike in pressure. It is also licensed as a short-term addition, usually for no more than a month, when other drugs are not controlling the pressure.
Pilocarpine is a muscarinic agonist and the oldest glaucoma drug. It has two separate useful actions. It contracts the longitudinal fibres of the ciliary muscle, which pull on the scleral spur and open the spaces of the trabecular meshwork, increasing conventional outflow. And it contracts the iris sphincter, constricting the pupil and drawing the peripheral iris away from the angle, which is why it is used in angle closure.
Its side effects follow from the same actions. The small pupil dims vision, especially at night and in patients with central lens opacities. Ciliary muscle spasm causes brow ache and, in younger patients, a variable induced myopia. Retinal detachment has been reported, so the BNF advises a fundus examination before starting. Pilocarpine is contraindicated in acute iritis and anterior uveitis, where a small pupil encourages adhesions to the lens. It needs dosing up to four times a day, and it is now rarely used for long-term treatment of open-angle glaucoma.
Rho kinase inhibitors
Netarsudil is the newest class in UK practice, available as a fixed combination with latanoprost. Rho kinase keeps the cells of the trabecular meshwork and Schlemm's canal contracted and stiff. Inhibiting it relaxes their cytoskeleton, so aqueous passes through the conventional pathway more easily. It acts directly on the cells of the outflow pathway that is at fault in open-angle glaucoma.
NICE recommends latanoprost with netarsudil as an option for adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not lowered pressure enough, and only if a fixed-dose combination has then been tried without success or one containing a beta-blocker is unsuitable. Conjunctival hyperaemia is the main side effect. Small conjunctival haemorrhages and cornea verticillata, a whorl-like deposit in the corneal epithelium, also occur.
Using drops well
Glaucoma drops are taken for decades by people who feel no benefit from them, so adherence and technique decide whether treatment works. NICE asks clinicians to demonstrate instillation and to watch the patient do it when drops are first prescribed, and to check adherence and technique before concluding that a drug has failed.
- One drop is enough. The conjunctival sac cannot hold more.
- Punctal occlusion: closing the eye and pressing on the inner corner for a minute or more after the drop reduces drainage into the nose and so reduces systemic absorption.
- Leave an interval of several minutes between different drops so that the second does not wash out the first.
- Fixed combinations in one bottle reduce the number of drops and the exposure to preservative.
- Preservative-free preparations are for people who are allergic to preservatives or have significant ocular surface disease.
| Patient | Avoid | Reason |
|---|---|---|
| Asthma, heart block or bradycardia | Beta-blockers | Bronchospasm and worsening conduction block |
| Active herpes simplex keratitis | Prostaglandin analogues | Contraindicated in the BNF |
| Active anterior uveitis | Pilocarpine | Contraindicated in the BNF |
| Sulfonamide hypersensitivity | Acetazolamide and brinzolamide, with caution for dorzolamide | Sulfonamide derivatives |
| Infant or young child | Brimonidine | Central nervous system depression |
Summary
- Glaucoma drugs either reduce aqueous production or increase outflow, and drugs with different mechanisms combine best.
- Prostaglandin analogues increase uveoscleral outflow, lower pressure by about 30 per cent, are given once daily in the evening and are first line.
- Prostaglandin analogues darken the iris by increasing melanin in melanocytes, lengthen the lashes and can cause cystoid macular oedema.
- Beta-blockers reduce aqueous production and are contraindicated in asthma, bradycardia and heart block because drops are absorbed systemically.
- Carbonic anhydrase inhibitors reduce aqueous production: dorzolamide and brinzolamide topically, acetazolamide systemically.
- Acetazolamide causes paraesthesia, metabolic acidosis, hypokalaemia and renal stones and is contraindicated in sulfonamide hypersensitivity.
- Brimonidine is an alpha-2 agonist that commonly causes allergic conjunctivitis and must be avoided in infants and young children.
- Pilocarpine increases trabecular outflow by contracting the ciliary muscle and constricts the pupil, and is contraindicated in anterior uveitis.
- Netarsudil is a rho kinase inhibitor that increases trabecular outflow and causes hyperaemia and cornea verticillata.
- Punctal occlusion reduces systemic absorption of any eye drop.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.